TG Therapeutics Inc (TGTX)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 12,672 | -198,335 | -348,101 | -279,381 | -172,870 |
| Total stockholders’ equity | US$ in thousands | 160,502 | 58,587 | 237,153 | 519,350 | 38,615 |
| ROE | 7.90% | -338.53% | -146.78% | -53.79% | -447.68% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $12,672K ÷ $160,502K
= 7.90%
TG Therapeutics Inc's return on equity (ROE) has varied significantly over the past five years. In 2023, the ROE improved to 7.90%, indicating a moderate profitability related to the shareholders' equity. This improvement is a positive sign compared to the negative ROE figures in the previous four years.
In 2022, the ROE was significantly negative at -338.53%, reflecting a substantial loss compared to the equity invested by shareholders. The negative ROE continued from 2021, where it was reported at -146.78%, indicating a troubling trend in the company's financial performance related to shareholder equity.
The ROE for 2020 was also negative at -53.79%, suggesting that the company struggled to generate profits relative to the equity invested that year. The lowest ROE in the dataset was in 2019 at -447.68%, indicating a considerable loss in shareholder value.
Overall, the improvement in ROE in 2023 is a positive indicator, but the company should continue to monitor and work towards consistently positive ROE figures to ensure sustainable profitability and shareholder value creation.
Peer comparison
Dec 31, 2023